Advances in B Cell Science: Clinician Update
A Report from the Annual International Rheumatology Meeting
A complimentary symposium offered in two locations
| September 16, 2009 12:00 pm – 5:00 pm InterContinental Hotel & Bank of America Conference Center Cleveland, OH |
October 3, 2009 7:00 am – 12:00 pm Hyatt Regency La Jolla San Diego, CA |
Description
In recent years, our understanding of autoimmune rheumatic diseases (ARDs) has led to encouraging advances in treatment. Reliance on therapies that affect a wide range of cellular targets is a thing of the past. The use of targeted biologic therapy is on the rise as further data emerge regarding their efficacy, utility, and safety. The increasing adoption of these agents into clinical practice challenges clinicians to remain informed and up to date regarding new data released at European annual conferences.
This symposium is designed for busy clinicians who are interested in keeping abreast of cutting-edge data and novel therapies in the treatment of ARDs. Expert faculty will bridge the gap between the current immunobiologic data and the day-to-day workings of clinical practice.
GOING GREENElectronic Syllabus: Syllabus will only be provided to registrants on a USB flash drive. Attendees are encouraged to bring their laptops to the symposium to view the syllabus. |
Target Audience
This educational activity is intended for rheumatologists, immunologists, clinical researchers, and allied health care professionals who care for patients with autoimmune rheumatic diseases.
Objectives
Upon completion of this symposium, the participant will be able to:
- Review advances in molecular biology that contribute to the understanding of B-cell biology, the integrated immune response, and the pathogenesis/clinical features of autoimmune rheumatic diseases;
- Summarize recently published clinical data relating to the usage of B-cell-directed therapies for rheumatoid arthritis;
- Examine current approaches and clinical methodology to the usage of B-cell-directed therapeutics in autoimmune rheumatic diseases;
- Describe the role of the allied health professional in the overall management of patients on B-cell-directed therapies from the perspective of patient counseling, assessing risks and benefits, administering and monitoring drug therapies, and assessing and managing drug-related toxicities;
- Assess the impact of biologic agents on the rates of serious infections, humoral immunity, and vaccine response.
Director
| Leonard Calabrese, DO Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Vice Chairman, Department of Rheumatic and Immunologic Diseases R.J. Fasenmyer Chair of Clinical Immunology Orthopaedics & Rheumatologic Institute Cleveland Clinic Cleveland, Ohio |
Faculty
| Marc D. Cohen, MD Professor of Medicine National Jewish Medical and Research Center Denver, Colorado |
| Jonathan Kay, MD Director of Clinical Research Rheumatology Division Professor of Medicine University of Massachusetts Medical School Worchester, Massachusetts |
| Peter Lipsky, MD Former Chief, Autoimmunity Branch National Institute of Arthritis & Musculoskeletal & Skin Diseases Bethesda, Maryland |
| Eamonn Molloy, MD, MS, MRCPI R.J. Fasenmeyer Center for Clinical Immunology / Center for Vasculitis Care and Research Department of Rheumatic and Immunologic Diseases Cleveland Clinic Cleveland, Ohio |
| Gregg J. Silverman, MD Professor of Medicine Director, Laboratory of B-Cell Immunology Division of Rheumatology, Allergy, and Immunology University of California San Diego School of Medicine La Jolla, California |
Agenda
| WEDNESDAY, SEPTEMBER 16, 2009 12:00 PM - 5:00 PM |
FRIDAY, OCTOBER 3, 2009 7:00 AM - 12:00 PM |
| InterContinental Hotel, Cleveland, OH | Hyatt Regency La Jolla, San Diego, CA |
| Moderator: Leonard Calabrese, DO |
Moderator: Gregg Silverman, MD |
| 12:00 pm Registration | 7:00 am Registration |
| 1:00 pm Welcoming Remarks | 8:00 am Welcoming Remarks |
| - Pathogenesis of Rheumatoid Arthritis: Are There Two Distinct Diseases? - Gregg Silverman, MD |
| - Advances in B-Cell–Directed Therapies in Rheumatoid Arthritis - Marc Cohen, MD |
| - Debate: What to do After the TNF Inhibitor Fails? Moderators: Leonard Calabrese, DO (Cleveland); Gregg Silverman, MD (San Diego) |
| - B-Cell Directed Therapy is the
Logical Next Choice -
Marc Cohen, MD
vs Another TNF Agent or Abatacept Is the Logical Next Choice - Jonathan Kay, MD |
| - Panel Discussion & Questions |
| - IL-21 Biology in Health and Disease - Peter Lipsky, MD (Cleveland); TBD (San Diego) |
| - Current Status of SLE Trials - Jonathan Kay, MD |
| - Emerging Safety Issues in Biologics 2009: Progressive Multifocal Leukoencephalopathy and Biologics - Leonard Calabrese, DO (Cleveland); Eamonn Molloy, MD (San Diego) |
| - Panel Discussion & Questions |
Locations
| September 16, 2009 InterContinental Hotel & Bank of America Conference Center 9801 Carnegie Avenue Cleveland, Ohio 44106 |
October 3, 2009 Hyatt Regency La Jolla 3777 La Jolla Village Drive San Diego, California 92112
|
| Click here for the Google Map location | Click here for the Google Map location |
Additional Information
For further information about this symposium, contact UNITECH Communications® at:
Local: 216-448-0770
Toll Free: 800-238-6750
For questions about registering online, call 216-448-0777 or email CMEregistration@ccf.org.
Faculty Disclosure
The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.
Americans with Disabilities Act
The Cleveland Clinic Foundation Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify UNITECH Communications® at 216-448-0770 or 800-238-6750 at least two weeks prior to the activity.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Online Registration/Fees
Registration fee includes includes refreshments and
electronic syllabus.
| Category | Either Event |
|---|---|
| All Attendees | complimentary |
